[Federal Register Volume 61, Number 39 (Tuesday, February 27, 1996)]
[Notices]
[Pages 7267-7268]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-4363]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES:  Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing specialist at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804 (telephone 301/496-7057; fax 301/402-0220). A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Azo Dye Derivatives Exhibiting Anti-HIV Activity, Pharmaceutical 
Compositions Containing the Same and Methods for Using the Same

Haugwitz, R.D., Zalkow, L., Deutsch, H., Gruszecka-Kowalik, E., Asibal, 
C., Qazi, S. (NCI)
Filed 7 Jun 95
Serial No. 08/479,540 (FWC of 08/167,296)
Licensing Contact: Cindy K. Fuchs, 301/496-7735 ext 232

    A method of obtaining substantially pure azo stilbenes offers an 
important new tool for combating HIV infection. A number of dyes have 
been shown to have anti-HIV activity; however, it has previously not 
been possible to purify the anti-HIV components of these compounds. 
This pure preparation of azo stilbenes have a broad range of antiviral 
activity, including anti-HIV activity. (portfolio: Infectious 
Diseases--Therapeutics, antivirals, AIDS)

Amido Substituted Stilbenes and Related Compounds With In Vitro Anti-
HIV Activity

Haugwitz, R.D., Zalkow, L., Gruszecka-Kowalik, E., Burgess, E. (NCI)
Filed 17 Feb 95
Serial No. 08/390,057
Licensing Contact: Gloria H. Richmond, 301/496-7056 ext 268

    Aroylaniline derivatives which exhibit antiviral activity, methods 
for synthesizing these compounds, pharmaceutical formulations 
containing these compounds, and methods for treating viral infection 
are described in this invention. The aroylaniline derivatives are 
capable of preventing the replication of virus in a cell, such as human 
T-cell, without staining the tissue. These compounds may effectively 
treat viral infections of mammals, particularly human. A main target 
for these compounds can be treatment against infections caused by 
retroviruses such as HIV. (portfolio: Infectious Diseases--
Therapeutics, antivirals, AIDS)

A Method for Isolating Dendritic Cells

Cohen, P.A., Czerniecki, B.J., Carter, C., Fowler, D.H., Kim, H. (NCI)
Filed 27 Jan 95
Serial No. 08/379,227
Licensing Contact: Stephen Finley, 301/496-7735 ext 215

    Antigen presenting cells (APCs) are cells that are involved in the 
presentation of antigens to the immune system. APCs can stimulate the 
immune system--T lymphocytes--to fight infections, including HIV and 
some forms of cancer. A wide variety of cells have the capability to 
act as APCs, including monocytes, macrophages, B cells, and dendritic 
cells; however, extensive research has indicated that the most potent 
antigen presenting cell is the dendritic cells. Previous methods for 
isolating dendritic cells have relied on either the isolation of bone 
marrow precursor cells from blood followed by 

[[Page 7268]]
stimulation to form dendritic cells, or the collection of precommitted 
cells from peripheral blood. Both of these methods have drawbacks: the 
necessity to treat the patient with cytokines to increase the number of 
precursor cells in the blood or techniques that lead to physical trauma 
of the dendritic cells. This invention embodies a method to isolate 
dendritic cells from blood in which leukapheresis is employed as a 
preliminary step to enrich for precursor cells in a patient without the 
requirement for cytokine treatment followed by countercurrent 
centrifugal elutriation. The purity of the cells isolated is much 
greater than any other known method. (portfolio: Central Nervous 
System--Research Tools and Reagents)

AAMP-1

Beckner, M.E., Liotta, L.A. (NCI)
Filed 25 Jun 93
Serial No. 08/083,945 (CIP of 07/827,043)
Licensing Contact: Susan Rucker, 301/496-7056 ext 245

    AAMP-1, a novel protein that has human cell adhesion properties has 
been characterized. Peptides derived from that protein have been shown 
to exhibit herparin-binding and cell-adhesive properties. The heparin-
binding properties of the peptides may be useful for the treatment of 
conditions in which the presence or absence of heparin and/or heparin-
sulfate needs to be regulated. These conditions could include 
heparinization to prevent blood clotting and possibly inflammatory, 
immune, or neoplastic disorders, and wound-healing in human patients. 
The cell-adhesion properties of the peptides may be useful for 
mediating cell-cell and cell-substrate adhesion. These properties might 
be particularly useful for producing materials for use in prosthetic 
devices-cell adhesion to a prosthetic device could potentially be 
controlled by regulating the presence or absence of heparin in the 
bodily system of the patient receiving a prosthetic device made with 
the peptides. The peptides retain their properties following 
crystallization, and the crystallized peptides are heat-stable and not 
inactivated by solvents. The small size and enhanced stability and 
processability of the crystalline peptides versus the native AAMP-1 
protein suggest that the peptides will be more useful therapeutic 
agents and better raw materials for device fabrication than the native 
protein. (portfolio: Cancer--Diagnostics, in vitro, other; Cancer--
Therapeutics, biological response modifiers)

Vaccine Against Hepatitis A Virus

Purcell, R.H., Ticehurst, J.R., Cohen, J.L., Emerson, S.U., Feinstone, 
S.M., Daemer, R.J., Gust, I.D. (NCI)
Filed 16 Jan 92
Serial No. 07/822,639 (Reissue of Serial No. 07/217,824; U.S. Patent 
No. 4,894,228 issued 16 Jan 90)
Licensing Contact: Gloria H. Richmond, 301/496-7056 ext 268

    An attenuated hepatitis A virus (HAV) offers an important new tool 
for the development of a protective vaccine. Previously, immune serum 
globulin (ISG) is the only effective vaccine for preventing HAV 
infection; however, ISG elicits only low levels of neutralizing 
antibodies and, thus, requires repeated doses. This attenuated HAV, 
which is a mutant of the wild-type strain, elicits serum-neutralizing 
antibody production in chimpanzees and is suitable for vaccine 
development. (portfolio: Infectious Diseases--Vaccines, viral, non-
AIDS)

    Dated: February 20, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-4363 Filed 2-26-96; 8:45 am]
BILLING CODE 4140-01-M